Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia

MONTREAL, Jan. 25, 2016 /PRNewswire/ - Milestone Pharmaceuticals Inc., a clinical stage cardiovascular company, announced today that the United States Adopted Name (USAN) Council recently adopted "etripamil" as the unique non-proprietary or generic name for MSP-2017.

The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique nonproprietary names for drugs by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships.

"We are pleased to have etripamil approved as the generic name for MSP-2017," said Philippe Douville, Chief Executive Officer of Milestone. "The receipt of a USAN generic name is an exciting step forward as we continue to advance our NODE-1, Phase 2 clinical study with etripamil for paroxysmal supraventricular tachycardia. Etripamil could improve patients' quality of life by allowing them to terminate their PSVT episodes at home and minimize inpatient hospital treatments and/or emergency room visits."

About Etripamil (formerly MSP-2017)

Etripamil is being developed as a patient self-administered intranasal spray to terminate paroxysmal supraventricular tachycardia (PSVT) at the onset of episodes and is currently being evaluated in a Phase 2 clinical trial (NODE-1) in the United States and Canada. Etripamil is a novel and potent short-acting calcium channel antagonist intended for the treatment of patients with PSVT, a potentially debilitating cardiac arrhythmia.  Phase 1 results showed that etripamil had a rapid onset and reached pharmacologically relevant plasma levels within 5 minutes of administration. Etripamil is designed to be short-acting and metabolized quickly after resolution of the PSVT episode to avoid the potential complications of current long-term therapies.

Etripamil is intended to address an important unmet medical need in patients who demand a convenient, rapidly efficacious and safe self-administered product for the treatment of PSVT episodes in the home setting.  Information regarding the NODE-1 clinical study may be found at www.clinicaltrials.gov (study identifier NCT02296190).

About Paroxysmal Supraventricular Tachycardia

Paroxysmal supraventricular tachycardia is a condition that afflicts 1.7 million people and results in over 600,000 healthcare claims in the US alone per year. During a PSVT episode, patients may feel palpitations while heart rate increases dramatically and can exceed 200 beats per minute. Although the condition is not life threatening, it causes great concern on the part of the patient and generally results in an emergency trip to the hospital. In the emergency room, the patient is usually administered intravenous drugs and observed until symptoms disappear.

About Milestone Pharmaceuticals

Milestone is a clinical stage drug development company developing novel small molecule therapeutics based on clinically validated mechanisms of action for cardiovascular diseases. Milestone's lead product, etripamil, is a novel and potent short-acting calcium channel antagonist for the systemic treatment of PSVT in Phase 2 clinical studies. The Company has assembled a world-class drug development team and advisory board of key opinion leaders with significant cardiovascular expertise in cardiology, regulatory affairs, and drug development. For more information, please visit www.milestonepharma.com.

SOURCE Milestone Pharmaceuticals Inc.

Related Links

http://milestonepharma.com